BRPI0516483A - preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade - Google Patents

preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade

Info

Publication number
BRPI0516483A
BRPI0516483A BRPI0516483-4A BRPI0516483A BRPI0516483A BR PI0516483 A BRPI0516483 A BR PI0516483A BR PI0516483 A BRPI0516483 A BR PI0516483A BR PI0516483 A BRPI0516483 A BR PI0516483A
Authority
BR
Brazil
Prior art keywords
obesity
biphenyl
treatment
preparation
acid derivatives
Prior art date
Application number
BRPI0516483-4A
Other languages
English (en)
Inventor
Roger Smith
Stephen J O'connor
Philip Coish
Derek Lowe
Roger B Clark
Jeffrey Stebbins
Ann-Marie Campbell
Christiana Akuche
Tatiana Shelekhin
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BRPI0516483A publication Critical patent/BRPI0516483A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

PREPARO E USO DE DERIVADOS DE áCIDO BIFENIL-4-IL-CARBONILAMINO PARA O TRATAMENTO DE OBESIDADE. A presente invenção refere-se a determinados compostos de ácido bifenil-4-iI carbonilamino, composições e métodos para o tratamento ou prevenção de obesidade e doenças relacionadas.
BRPI0516483-4A 2004-10-15 2005-10-14 preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade BRPI0516483A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61897504P 2004-10-15 2004-10-15
PCT/US2005/037215 WO2006044775A2 (en) 2004-10-15 2005-10-14 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity

Publications (1)

Publication Number Publication Date
BRPI0516483A true BRPI0516483A (pt) 2008-09-02

Family

ID=36203612

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516483-4A BRPI0516483A (pt) 2004-10-15 2005-10-14 preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade

Country Status (21)

Country Link
US (2) US7759376B2 (pt)
EP (1) EP1805156B1 (pt)
JP (1) JP2008516978A (pt)
KR (1) KR20070063546A (pt)
CN (1) CN101087769A (pt)
AT (1) ATE492542T1 (pt)
AU (1) AU2005295453A1 (pt)
BR (1) BRPI0516483A (pt)
CA (1) CA2583784A1 (pt)
CR (1) CR9034A (pt)
DE (1) DE602005025517D1 (pt)
EA (1) EA200700851A1 (pt)
EC (1) ECSP077397A (pt)
ES (1) ES2357015T3 (pt)
IL (1) IL182218A0 (pt)
MA (1) MA28935B1 (pt)
MX (1) MX2007004217A (pt)
NO (1) NO20072461L (pt)
TN (1) TNSN07111A1 (pt)
WO (1) WO2006044775A2 (pt)
ZA (1) ZA200703002B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007101A (es) 2004-12-14 2007-08-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
JP5117391B2 (ja) 2005-11-21 2013-01-16 アナディス ファーマシューティカルズ インク ５−アミノ−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンを調製するための新規な方法
WO2007071966A1 (en) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido- [4, 5-b] -oxazines for use as dgat inhibitors
CN101415683B (zh) 2006-03-31 2013-07-17 诺瓦提斯公司 新化合物
BRPI0712796A2 (pt) 2006-05-30 2012-10-02 Astrazeneca Ab composto, métodos para produzir uma inibição da atividade de dgat1 em um animal de sangue quente, para tratar a diabete melito e/ou a obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para um composto
KR20090012349A (ko) 2006-05-30 2009-02-03 아스트라제네카 아베 아세틸 조효소 ａ 디아실글리세롤 아실트랜스퍼라제의 억제제로서의 치환된 5-페닐아미노-1,3,4-옥사디아졸-2-일카르보닐아미노-4-페녹시-시클로헥산 카르복실산
KR100795462B1 (ko) 2006-09-27 2008-01-16 한국생명공학연구원 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
KR100811100B1 (ko) 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
PE20080888A1 (es) 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
KR20090098877A (ko) * 2006-12-11 2009-09-17 노파르티스 아게 심근 허혈의 예방 또는 치료 방법
CA2687918C (en) * 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
AU2008258487B2 (en) 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
ES2558152T3 (es) 2007-06-08 2016-02-02 Janssen Pharmaceutica, N.V. Derivados de piperidina/piperazina
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
PE20091682A1 (es) 2007-12-20 2009-12-04 Astrazeneca Ab Compuestos de carbamoilo como inhibidores de dgat1 190
UA105178C2 (ru) 2008-05-05 2014-04-25 Санофи-Авентис Ациламинозамещенные производные конденсированных циклопентанкарбоновых кислот и их применение как фармацевтических средств
PE20100083A1 (es) 2008-06-05 2010-02-17 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
AR075319A1 (es) * 2008-12-23 2011-03-23 Novartis Ag Compuestos de biaril- bencil-amina, procesos para su produccion, su uso como productos farmaceuticos, y composiciones farmaceuticas que los comprenden
US20110319396A1 (en) * 2009-01-23 2011-12-29 Msd K.K. Benzodiazepin-2-on derivatives
EP2408774B1 (en) 2009-03-20 2014-11-26 Metabasis Therapeutics, Inc. Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof
US8268820B2 (en) 2009-03-26 2012-09-18 Hoffmann-La Roche Inc. 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
EP2443096A1 (en) 2009-06-19 2012-04-25 AstraZeneca AB Pyrazine carboxamides as inhibitors of dgat1
AR079022A1 (es) * 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
EP2496564A2 (en) 2009-11-05 2012-09-12 Piramal Life Sciences Limited Heteroaryl compounds as dgat-1 inhibitors
JP5746977B2 (ja) * 2009-12-16 2015-07-08 ポーラ化成工業株式会社 色素沈着予防又は改善剤
BR112012024618A2 (pt) 2010-03-30 2019-09-24 Novartis Ag usos de inibidores de dgat1
WO2012150784A2 (ko) 2011-05-03 2012-11-08 한국생명공학연구원 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9499482B2 (en) 2012-09-05 2016-11-22 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892896B1 (en) 2012-09-05 2016-06-29 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
USRE49575E1 (en) * 2014-08-01 2023-07-11 Bayer Pharma Aktiengesellschaft Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-l,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
CN105646510A (zh) * 2014-12-02 2016-06-08 重庆宁牧生态农业有限公司 一种用作抗肥胖剂的化合物
EP3983084A1 (en) * 2019-06-12 2022-04-20 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN112336718A (zh) * 2020-10-19 2021-02-09 济南大学 一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用
WO2023085931A1 (en) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatic organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4164645B2 (ja) * 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
WO2004047755A2 (en) * 2002-11-22 2004-06-10 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
AR044152A1 (es) * 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad

Also Published As

Publication number Publication date
ZA200703002B (en) 2008-08-27
EA200700851A1 (ru) 2007-12-28
US20110118302A1 (en) 2011-05-19
WO2006044775A3 (en) 2006-06-15
ATE492542T1 (de) 2011-01-15
EP1805156B1 (en) 2010-12-22
KR20070063546A (ko) 2007-06-19
US20070265298A1 (en) 2007-11-15
CA2583784A1 (en) 2006-04-27
MA28935B1 (fr) 2007-10-01
WO2006044775A2 (en) 2006-04-27
CR9034A (es) 2008-11-18
TNSN07111A1 (en) 2008-06-02
IL182218A0 (en) 2007-09-20
EP1805156A4 (en) 2009-06-10
CN101087769A (zh) 2007-12-12
MX2007004217A (es) 2007-06-11
US7759376B2 (en) 2010-07-20
ES2357015T3 (es) 2011-04-15
AU2005295453A1 (en) 2006-04-27
DE602005025517D1 (de) 2011-02-03
NO20072461L (no) 2007-07-03
ECSP077397A (es) 2007-05-30
EP1805156A2 (en) 2007-07-11
JP2008516978A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
ECSP056210A (es) Preparación y uso de derivados de alquilarilo para el tratamiento de la obesidad
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CR10099A (es) Inmunoglobulinas dirigidas contra nogo
TW200745122A (en) New compounds I
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
WO2009051718A3 (en) Calcium receptor modulating agents
EA200801425A1 (ru) Диазепиноны
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
TW200745133A (en) New compounds II
WO2007059356A3 (en) Furfurylidene- pyrazolidines and their use as inhibitors of ubiquitin e1
HN2003000104A (es) Derivados de ciclopenteno
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.